

1 **DIAGNOSTIC ACCURACY OF NON-INVASIVE DETECTION OF SARS-COV-2**
2 **INFECTION BY CANINE OLFACTION**
3
4

5 Dominique GRANDJEAN¹, Caroline ELIE^{2,3}, Capucine GALLET¹, Clotilde JULIEN¹, Vinciane ROGER¹, Loïc
6 DESQUILBET¹, Guillaume ALVERGNAT⁴, Séverine DELARUE⁷, Audrey GABASSI⁷, Marine MINIER⁷, Laure
7 CHOUPEAUX², Solen KERNEIS^{5,6}, Constance DELAUGERRE⁷, Jérôme LE GOFF⁷, Jean-Marc TRELUYER^{2,3}

8
9 **Affiliations of the authors**

10
11 ¹ Ecole Nationale Vétérinaire d'Alfort (Alfort School of Veterinary Medicine), University Paris-Est,
12 Maisons-Alfort, France

13 ² Unité de Recherche Clinique / Centre Investigation Clinique, APHP, Hôpital Necker-Enfants malades,
14 F-75015 Paris, France

15 ³ Université de Paris, EA 7323 Pharmacologie et thérapeutique de l'enfant et de la femme enceinte,
16 F-75015 Paris, France

17 ⁴ International Affairs Bureau, Ministry of Interior of the UAE, United Arab Emirates

18 ⁵ Université de Paris, INSERM, IAME, F-75018 Paris, France

19 ⁶ Equipe de Prévention du Risque Infectieux, AP-HP, Hôpital Bichat, F-75018 Paris, France

20 ⁷ Service de Virologie, AP-HP, Hôpital Saint Louis, F-75010 Paris, France

21
22 **Corresponding Author:** Jean-Marc Tréluyer, MD, Unité de Recherche Clinique, Hôpital Necker-

23 Enfants malades, 149, rue de Sèvres, 75015 Paris, France; Phone: +33 1 58413481; Fax: +33 1

24 44495950;

25 Email: jean-marc.treluyer@aphp.fr

26 **Running title:** Detection of SARS-CoV-2 infection by canine olfaction

27

28 **ABSTRACT**

29 **BACKGROUND**

30 Throughout the COVID-19 pandemic, testing individuals remains a key action. One approach to rapid
31 testing is to consider the olfactory capacities of trained detection dogs.

32 **METHODS**

33 Prospective cohort study in two community COVID-19 screening centers. Two nasopharyngeal swabs
34 (NPS), one saliva and one sweat samples were simultaneously collected. The dog handlers (and the
35 dogs...) were blinded with regards to the Covid status. The diagnostic accuracy of non-invasive
36 detection of SARS-CoV-2 infection by canine olfaction was assessed as compared to nasopharyngeal
37 RT-PCR as the reference standard, saliva RT-PCR and nasopharyngeal antigen testing.

38 **RESULTS**

39 335 ambulatory adults (143 symptomatic and 192 asymptomatic) were included. Overall, 109/335
40 participants tested positive on nasopharyngeal RT-PCR either in symptomatic (78/143) or in
41 asymptomatic participants (31/192). The overall sensitivity of canine detection was 97% (95% CI, 92
42 to 99) and even reached 100% (95% CI, 89 to 100) in asymptomatic individuals compared to NPS RT-
43 PCR. The specificity was 91% (95% CI, 72 to 91), reaching 94% (95% CI, 90 to 97) for asymptomatic
44 individuals. The sensitivity of canine detection was higher than that of nasopharyngeal antigen
45 testing (97% CI: 91 to 99 versus 84% CI: 74 to 90, $p=0.006$), but the specificity was lower (90% CI: 84
46 to 95 versus 97% CI: 93 to 99, $p=0.016$).

47 **CONCLUSIONS**

48 Non-invasive detection of SARS-CoV-2 infection by canine olfaction could be one alternative to NPS
49 RT-PCR when it is necessary to obtain a result very quickly according to the same indications as
50 antigenic tests in the context of mass screening.

51

52 INTRODUCTION

53 Facing the COVID-19 crisis, early and efficient screenings are needed to limit the spread of the virus,
54 allowing for the prompt isolation of positive individuals, a key action in this constant fight. Presently,
55 most ongoing diagnostic COVID-19 testing involves nasopharyngeal sampling for RT-PCR,
56 nasopharyngeal point-of-care antigen testing or saliva RT-PCR to identify the pathogen.
57 Nasopharyngeal sampling for RT-PCR is the reference test but has the drawback of invasiveness and
58 discomfort (nasopharyngeal sampling) and/or delay (RT-PCR) in obtaining the result.

59 Volatile organic compounds (VOC) have the potential to become a revolutionary and non-invasive
60 approach to medical diagnostic in humans for conditions like cancer and degenerative or infectious
61 diseases. Aksenov [1,2] studied the VOCs produced by cultures of B-lymphocytes infected by three
62 influenza viruses: avian H9N2, avian H6N2 and human H1N1. The families of collected VOCs turned
63 out to be unique and specific to each viral subtype. The authors concluded that the minor alterations
64 induced by the virus on the cell's genome expression led to a specific change in the production of
65 VOCs in the cellular metabolism. Recently, Abd El Qader [3] showed the specificity of bacterial or
66 viral species in the VOCs produced by infected cell cultures. Schivo [4] also identified a specific
67 volatilome on airway cells infected by a rhinovirus. Canine olfactory detection capacities have been
68 utilized for years in police enforcement to detect narcotics or forensic remains, explosives, bank
69 notes, for human search and rescue missions and even to locate landmines.

70 Our hypothesis, the object of our previous proof of concept [5], was based on the potential excretion
71 of specific VOCs in the sweat, induced by SARS-CoV-2 cellular actions or replications generating VOCs
72 that the dogs can detect.

73 The objective of this prospective blinded multicenter study was to compare the diagnostic accuracy
74 of the detection of SARS-CoV-2 infection by canine olfaction with the current reference standard
75 (nasopharyngeal RT-PCR) and two alternate diagnostic strategies (nasopharyngeal antigenic test and
76 saliva RT-PCR) in community testing centers.

77

78

79 **MATERIALS AND METHODS**

80 This research is part of the “SALICOV-APHP” study (Evaluation of a strategy of SARS-CoV-2 infection
81 testing on a general population, based on the utilization of new detection or diagnostic orientation
82 approaches), promoted by Assistance Publique-Hôpitaux de Paris, France. The SALICOV-APHP study
83 was approved the Protection of Persons Committee (CPP) Ile-de France III (number 3840-NI) and is
84 registered on clinicaltrials.gov (NCT04578509). The protocol was approved for the dogs by the
85 committee on the ethics of animal experiments of the Ecole Nationale Vétérinaire d’Alfort. All
86 research procedures were employed in accordance with the relevant guidelines and regulations.

87 **Recruitment of participants**

88 Participants were recruited from two COVID screening centers in Paris piloted by APHP. Informed
89 consent was obtained from all subjects. Eligible persons received detailed oral and written
90 information[6]. Participants were prospectively enrolled if they were not opposed to participating in
91 the study. The following data were collected: age, gender, medical background, current symptoms
92 (temperature higher than 37.8°C, chills, cough, rhinorrhea, muscular pain, loss of olfaction or taste,
93 persisting headache, severe asthenia, etc.) and their onset date, alcohol/coffee/food/tobacco
94 consumption or tooth cleaning within 2 hours and 24 hours prior to the test.

95 **Samples**

96 Sweat samples were collected by dedicated APHP sampling teams by asking the participants to place
97 two sterile surgical compresses under their armpits for 2 min. Samples were stored in sterile medical
98 anti-UV glass containers, disinfected by the sampler’s helper, anonymously coded, then placed into a
99 second plastic envelope. Individual anonymous data were registered by APHP staff for each coded
100 sample. All samples were transferred within the day of collection from the sampling site to the
101 testing site in coolers that were cleaned and disinfected with a 10% aqueous acetone solution after
102 each use. All samples were stored until they were to be sniffed by the dogs in a minus 20°C freezer
103 and were never manipulated without disposable surgical gloves to prevent contamination.

104 Nasopharyngeal samples (NPS) were collected by a trained nurse, and participants were asked to
105 self-collect the saliva sample after swishing saliva in their mouths for 30 seconds [6].

106 **Canine resources**

107 The dogs involved in this study belong to French fire departments (Service départemental d'Incendie
108 et de Secours – SDIS of Yvelines and Oise) and to the Ministry of the Interior of the United Arab
109 Emirates (provided on the occasion to increase the number of operational dogs involved).

110 They all were trained in the same way according to the training protocol we developed in a previous
111 publication, with line-ups of positive and negative olfaction cones based on positive reinforcement
112 (toys) and validated similarly for their individual sensitivities and specificities [5].

113 The welfare of the dogs was fully respected, with toy rewards and a total absence of work-induced
114 physical or mental fatigue. This study was carried out in strict accordance with the recommendations
115 published in the guide for the care and use of animals edited by French law (articles R214-87 to
116 R214-137 of the French Rural Code).

117 **Testing protocol**

118 The testing sessions took place in a dedicated room (Figures 1) in the Alfort School of Veterinary
119 Medicine. A line-up consisting of 10 olfaction cones was placed in the room. During trials, all the
120 cones contained the unfamiliar samples, so neither the dog handlers, the data recorder nor any of
121 the individuals present knew anything about the positivity/negativity of the samples. Once the dogs
122 had performed the line-up, the cones and the background were cleaned with high pressure vapor,
123 new samples were placed and a new trial cycle could start. For each new sample placement, the
124 person in charge had to wear new disposable gloves (of the same brand during the entire period of
125 testing sessions) and a mask in order not to contaminate the olfactory environment. Each line-up was
126 sniffed by at least two dogs in order to mimic a real operational situation.

127 **Nasopharyngeal and saliva RT-PCR**

128 For nasopharyngeal and saliva samples, nucleic acid extraction was performed with the MGIEasy
129 Nucleic Acid Extraction Kit (MGI Tech Co, Shenzhen, China) on an MGISP-960 instrument (MGI Tech
130 Co). SARS CoV-2 RNA amplification was performed using the TaqPath™ COVID-19 CE IVD RT PCR Kit
131 (Thermo Fisher Scientific, Coutaboeuf, France). This technique provides results expressed as a cycle
132 threshold (Ct) for each gene target (ORF1ab, N and S genes) [6].

133 **Detection of other pathogens in saliva**

134 The detection of other viruses (adenovirus, coronaviruses (229E, HKU1, NL63, and OC43), human
135 metapneumovirus A and B, influenza , influenza A H1, influenza A H3, influenza A H1N1/2009,
136 influenza B, parainfluenza viruses (1, 2, 3, and 4), rhinovirus/enterovirus, respiratory syncytial virus A
137 and B) and intracellular bacteria (*Bordetella pertussis*, *Chlamydomphila pneumoniae*, and *Mycoplasma
138 pneumoniae*) was performed in saliva samples with the multiplex test QIAstat-Dx® Respiratory SARS-
139 CoV-2 Panel QIAstat (Qiagen, Courtaboeuf, France). Briefly, 100 µL of saliva was mixed with 400 µL of
140 NeuMoDx Viral Lysis Buffer (NeuMoDx Molecular, Inc., Ann Arbor, MI). Then 300 µl of the mix was
141 immediately added to the SARS-CoV-2 Panel cartridge placed into the QIAstat Dx Analyzer System
142 (Qiagen). The QIAstat-Dx Analyzer software processes controls, interprets the sample data and
143 provides Ct values for detected targets.

144 **Statistical analysis**

145 Sample size was calculated assuming that the sensitivity of the index tests was greater than or equal
146 to 60%. To allow sufficient precision ($\pm 10\%$), 93 subjects with positive nasopharyngeal RT-PCR results
147 were needed in each of the two subgroups (symptomatic and asymptomatic participants). To
148 account for samples excluded for technical reasons, a sample size of 110 subjects with positive
149 nasopharyngeal RT-PCR results was needed in each of these subgroups. As preliminary results
150 indicate that viral loads were not different between symptomatic and asymptomatic patients, the
151 scientific committee of the study, during a planned meeting on December 16, 2020, recommended
152 performing the analysis as soon as 93 subjects with positive nasopharyngeal RT-PCR results were
153 included, whether symptomatic or asymptomatic.

154 RT-PCR results were considered positive if at least one gene was detected. For the RT-PCR technique,
155 the Ct values reported are those for the ORF1a gene, and if not amplified, for the N gene (and for the
156 S gene if the N gene was not amplified).

157 An uncertain canine detection test (the dog shows great interest in the sample, but does not
158 immediately sit down) was considered positive. For samples that were processed by three or more
159 dogs, only the results of two dogs were recorded at random. A sample was considered positive if
160 both dogs marked the sample, and negative in all other cases.

161 Quantitative data were expressed as medians [interquartile range], and qualitative data as numbers
162 (percentages). The diagnostic accuracy of the index tests was evaluated by calculating sensitivity and
163 specificity. Confidence intervals were calculated by the exact binomial method. Subgroup analyses
164 were performed according to: i) the presence of symptoms on the day of testing, ii) the Ct value of
165 the nasopharyngeal RT-PCR, expressed as low (at least one of the 3 targets with Ct \leq 28, i.e. high viral
166 shedding) or high (all 3 targets with Ct $>$ 28, i.e. low viral shedding), iii) the consumption of alcohol,
167 coffee, food and smoking or tooth brushing before sample collection and iv) proven previous
168 infection with SARS-CoV-2.

169 Sensitivity analyses were performed considering 6 alternate criteria for positivity for the reference
170 standard: i) \geq 2 positive targets with nasopharyngeal RT-PCR, ii) \geq 1 positive target with
171 nasopharyngeal RT-PCR and at least one of the 3 targets with Ct $<$ 32, iii) \geq 1 positive target with
172 saliva RT-PCR, iv) \geq 1 positive target with either nasopharyngeal or saliva RT-PCR, v) \geq 1 positive
173 target with either nasopharyngeal or saliva RT-PCR and at least one of the 3 targets with Ct $<$ 32 and
174 vi) nasopharyngeal antigen test.

175 Quantitative variables were compared with Wilcoxon's test, with a significance level of 5%. The
176 sensitivity and specificity of canine detection and nasopharyngeal antigen tests were compared with
177 McNemar's test. The statistical analysis was performed using R software (<http://cran.r-project.org/>).
178 The reporting of results followed the Standards for Reporting Diagnostic accuracy studies (STARD
179 2015) guideline [7].

180

181 RESULTS

182 The flow of participants is described in Figure 2. Between March 16 and April 9, 2021, 516
183 participants were included in SALICOV-APHP study, 403 of whom agreed to provide an axillary
184 sample. Among them, 68 were excluded; 335 patients were thus analyzed. The proportions of
185 females and males were similar and median age of study participants was 35 years [25-49] (Table 1).
186 The reasons expressed by the individuals to be tested were the presence of symptoms (41.2%), being
187 contact cases (45.7%) or others (travel, voluntary testing, etc., 13.1%). Among the participants, 43%
188 presented with symptoms on the day of testing. The median time since the last contact and since the
189 first clinical symptom was 5 days [0-7] and 2 days [1-3], respectively.

190 Among the 335 participants, 109 (32.5%) tested positive on nasopharyngeal RT-PCR. The sensitivities
191 and specificities for all the participants and according to the presence/absence of symptoms are
192 presented in Table 2. The overall sensitivity of canine detection was 97% (95% CI, 92 to 99), reaching
193 100% (95% CI: 89-100) for asymptomatic individuals. The specificity was 91% (95% CI, 87 to 95),
194 reaching 94% (95% CI, 90 to 97) for asymptomatic individuals. The PPV and NPV (Positive and
195 Negative Predictive Values) were 84% (95% CI, 77 to 90) and 99% (95% CI, 85 to 99), respectively. The
196 sensitivity and specificity analysis of the diagnostic accuracy of the canine detection, as compared to
197 other reference tests, is presented in Table 3.

198 Measures of diagnostic accuracy did not differ according to different subgroups: with or without a
199 medical history of COVID, and having received medical treatment or not, tobacco, alcohol or coffee,
200 and gender (data not shown). In addition, sensitivities were similar for high ($Ct \leq 28$) and low ($Ct >$
201 28) viral loads: 97% (95% CI, 92 to 99) and 100% (95% CI, 59 to 100), respectively.

202 Among the 234 participants who agreed to the nasopharyngeal antigenic test, the sensitivity of
203 canine detection was greater than that of the antigenic test (97% CI: 91 to 99 versus 84% CI: 74 to 90,
204 $p=0.006$), but the specificity was lower (90% CI: 84 to 95 versus 97% CI: 93 to 99, $p=0.016$).

205 To assess if the infection with other respiratory viruses could interfere with canine olfaction, saliva
206 samples were tested with a multiplex PCR assay. Remaining saliva samples were available for 283
207 out of 335 participants. Out of these 283 saliva samples, 87 saliva were positive for SARS-CoV-2 and

208 25 samples were positive for another pathogen : rhinovirus/enterovirus (n = 11), human
209 coronaviruses (3 OC43 and 2 NL63), parainfluenza 3 (n = 2), bocavirus (n = 1), VRS (n = 2), bocavirus /
210 VRS (n = 1), Influenza A H1 (n = 1), human metapneumovirus (n = 1), Bordetella pertussis (n = 1).
211 Three co-infection with SARS-CoV-2 was identified. Out of 20 individuals tested negative for SARS-
212 CoV-2 in NPS samples but found positive with canine olfaction, 17 samples were tested for multiplex
213 detection in saliva. Fourteen had no other pathogene, two were positive for a coronavirus (NL63 and
214 OC43) and one was positive for SARS-CoV-2. For the diagnosis of viral respiratory infection (other
215 than SARS-CoV-2 infection), the sensitivity of canine detection was 20% (95% CI, 7% -41%) and the
216 specificity was 62% (95% CI, 56% -68%).

217

218

219 **DISCUSSION**

220 Our results show the excellent sensitivity of SARS-CoV-2 detection by dogs using nasopharyngeal RT-
221 PCR as the reference for comparison. These results are consistent with the results obtained
222 previously in proof of concepts studies using sweat in hospitalized patients [5,8–11].

223 To our knowledge, this study is the first one carried out prospectively in the context of SARS-CoV-2
224 screening and the first comparing dog detection and antigenic tests.

225 The results detailed showed no real difference in the sensitivity observed in the different subgroups:
226 sensitivity is always over 95% when specificity ranges from 83% to 95%.

227 The results obtained by canine detection using sweat samples are comparable to those of
228 nasopharyngeal antigenic tests. However, canine detection using sweat samples is less invasive than
229 antigenic tests on nasopharyngeal samples. Thus, the detection of SARS-CoV-2 infection by dogs
230 could be an alternative to antigenic tests.

231 Dog screening for SARS-CoV-2 seems specific for COVID-19 infection and not for viral infections in
232 general since only 2 among the 17 saliva samples in false positive patients were positive for a virus
233 other than SARS-CoV-2. Note, however, that in both cases, it was a coronavirus. We do not have
234 enough patients negative for SARS-CoV-2 and positive for other coronaviruses to know whether the
235 canine detection is specific for SARS-CoV-2 or for all coronaviruses.

236 Screening people directly, without going through sweat or saliva samples, could also be considered;
237 the advantage would certainly be increased speed. The disadvantage is the fear of dogs exhibited by
238 a significant number of individuals and the risk of dog contamination, which is not possible with the
239 system we have used. Direct detection by dogs should be further evaluated.

240

241 A limitation of non-invasive detection of SARS-CoV-2 infection by canine olfaction is the availability of
242 trained dogs in this approach in light of the very significant needs if canine detection were to be
243 considered as an alternative to antigenic tests. Another limitation is the need for certification of the
244 dogs used for SARS-CoV-2 detection because of the risk of involving dogs whose diagnostic
245 performance is inferior to those shown here. At the time of the study, there was no delta viriants
246 detected, but there is no reason to believe that the results would have been different in the presence
247 of the delta variants.

248 To conclude, the results obtained in our prospective study involving 335 individuals who presented
249 voluntarily in one of the APHP testing centers in Paris support the use of canine olfaction as an
250 alternative to antigenic tests. Canine testing is non-invasive and provides immediate and reliable
251 results. As for antigenic tests, positive results must be confirmed by RT-PCR, especially for variant
252 screening. Further studies will be focused on direct sniffing by dogs to evaluate sniffer dogs for mass
253 pre-test in airports, harbors, railways stations, cultural activities or sporting events. Axillary sweat
254 testing could remain useful for small population testing or for mobile units acting on local clusters as
255 an alternative to antigenic tests.

256

257

258 **Contributors**

259 Study concept and design: D.G., C.D., S.K., J.L.G., J.M.T.; Patients and controls recruitment: L. C., C.E.;
260 Data collection: C.G., C.J., V.R., L.D., G.A., S.D., A.G., M.M.; Analysis and interpretation of data: C.E,
261 J.M.T., D.G.; Drafting the manuscript: D.G., J.M.T. All the authors read and approved the final version
262 of the manuscript. The authors assume responsibility for the accuracy and completeness of the data
263 and analyses, as well as the adherence of the trial, its analyses and this report to the protocol.

264

265 **Funding**

266 The trial was supported by a grant from the French Ministry of Health, Region Ile de France and

267 Assistance Publique-Hôpitaux de Paris Foundation

268

269 **Declaration of interests**

270 All authors declare no competing interests

271

272 **Data sharing**

273 A data sharing statement provided by the authors is available with the full text of this article.

274 **Acknowledgments** We thank Quentin MUZZIN, Caroline ERDEVEN, Didier ROISSE, Nicolas DIRN,

275 Clément LEVERT, Erwan BRETON, Arnaud GALTAT, Fatma AL JASMI, Jamel ALHANAEE and Manea AL

276 BLOOSHI for their support in conducting this study, Naim Bouazza and Frantz Foissac for proofreading

277 the manuscript

278

279

280 References

- 281 1. Aksenov AA, Gojova A, Zhao W, Morgan JT, Sankaran S, Sandrock CE, et al. Characterization of
282 volatile organic compounds in human leukocyte antigen heterologous expression systems: a
283 cell's "chemical odor fingerprint." *Chembiochem*. 2012 May 7;13(7):1053–9.
- 284 2. Aksenov AA, Sandrock CE, Zhao W, Sankaran S, Schivo M, Harper R, et al. Cellular Scent of
285 Influenza Virus Infection. *ChemBioChem*. 2014;15(7):1040–8.
- 286 3. Abd El Qader A, Lieberman D, Shemer Avni Y, Svobodin N, Lazarovitch T, Sagi O, et al. Volatile
287 organic compounds generated by cultures of bacteria and viruses associated with respiratory
288 infections. *Biomed Chromatogr*. 2015 Dec;29(12):1783–90.
- 289 4. Schivo M, Aksenov AA, Linderholm AL, McCartney MM, Simmons J, Harper RW, et al. Volatile
290 emanations from in vitro airway cells infected with human rhinovirus. *J Breath Res*. 2014
291 Sep;8(3):037110.
- 292 5. Grandjean D, Sarkis R, Lecoq-Julien C, Benard A, Roger V, Levesque E, et al. Can the detection
293 dog alert on COVID-19 positive persons by sniffing axillary sweat samples? A proof-of-concept
294 study. *PLOS ONE*. 2020 déc;15(12):e0243122.
- 295 6. Kernéis S, Elie C, Fourgeaud J, Choupeaux L, Delarue SM, Alby M-L, et al. Accuracy of saliva and
296 nasopharyngeal sampling for detection of SARS-CoV-2 in community screening: a multicentric
297 cohort study. *Eur J Clin Microbiol Infect Dis*. 2021 Aug 3;
- 298 7. Bossuyt PM, Cohen JF, Gatsonis CA, Korevaar DA, STARD group. STARD 2015: updated reporting
299 guidelines for all diagnostic accuracy studies. *Ann Transl Med*. 2016 Feb;4(4):85.
- 300 8. Hag-Ali M, AlShamsi AS, Boeijen L, Mahmmod Y, Manzoor R, Rutten H, et al. The detection dogs
301 test is more sensitive than real-time PCR in screening for SARS-CoV-2. *Commun Biol*. 2021 Jun
302 3;4(1):1–7.
- 303 9. Sarkis R, Lichaa A, Mjaess G, Saliba M, Selman C, Lecoq-Julien C, et al. New method of screening
304 for COVID-19 disease using sniffer dogs and scents from axillary sweat samples. *J Public Health*
305 (Oxf). 2021 Jun 23;fdab215.
- 306 10. Angeletti S, Travaglino F, Spoto S, Pascarella MC, Mansi G, De Cesaris M, et al. COVID-19 sniffer
307 dog experimental training: Which protocol and which implications for reliable identification? *J*
308 *Med Virol*. 2021 Oct;93(10):5924–30.
- 309 11. Jendryn P, Schulz C, Twele F, Meller S, von Köckritz-Blickwede M, Osterhaus ADME, et al. Scent
310 dog identification of samples from COVID-19 patients - a pilot study. *BMC Infect Dis*. 2020 Jul
311 23;20(1):536.

312

313

314

315

316

317

318

319

320

321

Tables and Figures

322 Table 1: Characteristics of study participants. Results are presented as N (%) or medians [interquartile
323 ranges].

324

	Total (N=335)
Age — yr	35 [25-49]
Females — no. (%)	170 (51)
Contact with a confirmed case — no. (%)	153 (46)
Time since last contact — days	5 [0-7]
Presence of symptoms on the day of testing — no. (%)	143 (43)
Time from symptom onset — days	2 [1-3]
Cough — no. (%)	59 (41)
Headache — no. (%)	63 (44)
Rhinorrhea — no. (%)	53 (37)
Asthenia — no. (%)	58 (41)
Muscle pain — no. (%)	46 (32)
Fever — no. (%)	38 (27)
Diarrhea — no. (%)	107 (8)
Chills — no. (%)	7 (5)
Anosmia — no. (%)	10 (7)
Shortness of breath — no. (%)	7 (5)
Chest pain — no. (%)	7 (5)
Smoking in the last 24 hours — no. (%)	69 (21)
Consumption of alcohol in the last 24 hours — no. (%)	71 (21)
Consumption of coffee in the last hour — no. (%)	53 (16)
Tooth brushing in the last 2 hours — no. (%)	122 (36)
Mouth washing in the last 2 hours — no. (%)	6 (2)

325

326

327 Table 2: Diagnostic accuracy of canine detection as compared to the reference standard
328 (nasopharyngeal RT-PCR, positivity defined as at least one target gene being detected), according to
329 the presence of symptoms in study participants.
330
331

	Total, n	Positive sample, n	Sensitivity (95% CI*)	Specificity (95% CI*)
Overall	335	109	97% (92 to 99)	91% (87 to 95)
Symptoms	143	78	96% (89 to 99)	83% (72 to 91)
No symptom	192	31	100% (89 to 100)	94% (90 to 97)

332 *95% CI: 95% Confidence Interval

333
334

335 Table 3: Sensitivity analysis of the diagnostic accuracy of canine detection, as compared to several
 336 references.


Reference standard	Total, n	Positive samples, n	Sensitivity (95% CI*)	Specificity (95% CI)
NPS RT-PCR ≥ 2 targets	335	108	97% (92 to 99)	91% (86 to 94)
Symptoms	143	77	96% (89 to 99)	82% (70 to 90)
No symptoms	192	31	100% (89 to 100)	94% (90 to 97)
NPS RT-PCR ≥ 1 target and Ct value < 32	335	107	97% (92 to 99)	90% (86 to 94)
Symptoms	143	76	96% (89 to 99)	81% (69 to 89)
No symptoms	192	31	100% (89 to 100)	94% (90 to 97)
Saliva RT-PCR ≥ 1 target	320	80	90% (81 to 96)	81% (75 to 86)
Symptoms	136	53	96% (87 to 100)	65% (54 to 75)
No symptoms	184	27	78% (58 to 91)	89% (83 to 94)
NPS RT-PCR ≥ 1 target or Saliva RT-PCR ≥ 1 target	327	116	92% (86 to 96)	91% (87 to 95)
Symptoms	142	79	96% (89 to 99)	84% (73 to 92)
No symptoms	185	37	84% (68 to 94)	95% (90 to 98)
NPS RT-PCR ≥ 1 target or Saliva RT-PCR ≥ 1 target and Ct value < 32	327	112	95% (89 to 98)	91% (87 to 95)
Symptoms	142	78	96% (89 to 99)	83% (71 to 91)
No symptoms	185	34	91% (76 to 98)	95% (90 to 98)
NPS antigen	234	80	95% (88 to 99)	83% (76 to 89)
Symptoms	123	60	97% (88 to 100)	71% (59 to 82)
No symptoms	111	20	90% (68 to 99)	91% (83 to 96)

337 *95% CI : 95% Confidence Interval.

338

339

Figure 1B: Details of an olfaction cone, with a double-protected sample and no possibility of direct contact with the dog



DETAILS OF AN OLFACTION CONE

MARMELADE GLASS JAR

ANTI-UV GLASS JAR

SWAB WITH AXILARY SWEAT

HELPER WITH GLOVES

DEVICE IN PLACE BEHIND THE CONE

Figure 1C: Process involving olfaction cones and dog

OLFACTION CONES IN THE TRAINING ROOM



Figure 1D: Positive marking by a dog, sitting in front of a cone containing a positive sample

POSITIVE MARKING ON A CONE



Figure 1A: Testing room with its olfaction cones

OLFACTION CONES IN THE TESTING ROOM



Figure 2: Flowchart of the study

